Attention Deficit / Hyperactivity Disorder (ADHD).
Methylphenidate is indicated as part of a comprehensive treatment program for attention deficit hyperactivity disorder (ADHD) in children from 6 years of age when other measures by themselves have proved insufficient.
Diagnosis must be made according to DMS criteria or ICD-10 guidelines and must be based on the complete medical history and evaluation of the patient. The diagnosis cannot be established solely with the presence of one or more symptoms.
Download sheetRubifen® 5 mg tablets: white, round, flat tablets marked “RU” on one side and “5” on the other.
Rubifen® 10 mg tablets: white, round, flat, scored tablets marked “RU 10” on one side.
Rubifen® 20 mg tablets: white, round, flat, scored tablets marked “RU 20” on one side.
The slot serves only to divide the tablet and facilitate swallowing, but not to split into equal doses.
Treatment should be started under the supervision of a specialist in behavioral disorders in children and / or adolescents.
Pre-treatment screening
Before prescribing, a baseline assessment of the patient’s cardiovascular status, including blood pressure and heart rate, is required. Concomitant medication, past and present comorbid and psychiatric disorders or symptoms, a family history of sudden cardiac / unexplained death, and a detailed record of height and weight prior to treatment on a growth chart should be documented in the full medical history.
Dose adjustment
Careful dose adjustment is necessary when starting treatment with methylphenidate. Dose adjustment should be started with the lowest possible dose.
The maximum daily dose of methylphenidate is 60 mg daily.
Rubifen® is an immediate release formulation of methylphenidate. Treatment should be started with 5 mg once or twice a day (at breakfast and lunch), increasing the dose and the frequency of administration, if deemed necessary, at a rate of 5-10 mg weekly.
The total daily dose should be administered in several doses.
